Health Economics›Chronic lymphocytic leukemia›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Chronic lymphocytic leukemia · 25 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib and Ofatumumab Variant #01	—	R 8 431 136	28d	—	—	~8	~R 12 066 055 indirect	—
Lenalidomide and Ofatumumab Variant #01	—	R 2 208 004	28d	—	—	~23	~R 8 419 870 indirect	—
Bendamustine and Ofatumumab Variant #01	—	R 1 183 675	28d	—	—	~6	~R 3 259 566 indirect	—
Alemtuzumab and Rituximab Variant #01	—	R 517 306	28d	—	—	~2	~R 620 924 indirect	—
Ibrutinib, Venetoclax, Obinutuzumab Variant #01	—	R 295 786	28d	—	—	~14	~R 2 457 326 PFS proxy · indirect	2
Alemtuzumab monotherapy Variant #03	—	R 267 680	7d	~15.0 mo	—	~1	~R 267 680 PFS proxy · indirect	—
HDMP-R Variant #02	—	R 235 835	28d	—	—	~3	~R 344 838 indirect	—
Venetoclax monotherapy Variant #01	—	R 219 762	28d	—	—	~2	~R 439 524 indirect	—
Obinutuzumab monotherapy Variant #06	—	R 166 941	21d	—	—	~7	~R 310 033 indirect	—
Fludarabine and Alemtuzumab Variant #02	—	R 162 512	28d	~23.7 mo	—	~6	~R 537 050 PFS proxy · indirect	2
Ibrutinib and Rituximab Variant #02	—	R 157 847	28d	—	—	~8	~R 822 396 PFS proxy · indirect	3
Lenalidomide and Rituximab (R2) Variant #08	—	R 134 502	28d	~39.4 mo	—	~11	~R 396 684 PFS proxy · indirect	5
CFAR Variant #01	—	R 133 216	28d	—	—	~6	~R 643 866 indirect	—
PCR Variant #03 Partial	—	R 103 769	28d	—	—	~6	~R 208 140 indirect	—
Fludarabine and Ibrutinib Variant #01	—	R 93 887	28d	—	—	~5	~R 428 172 indirect	—
OFAR Variant #01	—	R 65 637	28d	—	—	~6	~R 238 397 indirect	—
DFCR Variant #01 Partial	—	R 60 250	28d	—	—	~26	~R 206 070 indirect	—
R-BAC Variant #01	—	R 59 061	28d	—	—	~4	~R 132 625 indirect	—
Ruxolitinib monotherapy Variant #06 Partial	—	R 48 520	—	—	—	~1	~R 48 520 PFS proxy · indirect	2
Fludarabine and Prednisone Variant #01	—	R 27 519	28d	—	—	~2	~R 55 037 indirect	—
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~30.8 mo	—	~13	~R 28 314 PFS proxy · indirect	2
Zanubrutinib and Obinutuzumab Partial	—	—	—	—	—	—	—	—
Idelalisib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Pirtobrutinib monotherapy Variant #01 Partial	—	—	28d	~14.0 mo	—	~2	—	1
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—

25 of 25 regimens shown